Analyst Price Targets — ZBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2026 9:59 am | Roger Song | Jefferies | $48.00 | $16.61 | StreetInsider | Zenas Biopharma (ZBIO) PT Lowered to $48 at Jefferies, 'we see clear path for approval (BLA submission planned in 2Q and MAA in 2H26') |
| January 5, 2026 8:39 pm | — | Morgan Stanley | $19.00 | $16.61 | TheFly | Zenas BioPharma downgraded to Equal Weight from Overweight at Morgan Stanley |
| October 28, 2025 10:08 am | — | H.C. Wainwright | $44.00 | $29.67 | TheFly | Zenas BioPharma price target raised to $44 from $30 at H.C. Wainwright |
| October 27, 2025 4:32 pm | Sean Laaman | Morgan Stanley | $34.00 | $31.65 | StreetInsider | Zenas Biopharma (ZBIO) PT Raised to $34 at Morgan Stanley |
| October 27, 2025 3:02 pm | Roger Song | Jefferies | $52.00 | $31.80 | StreetInsider | Zenas Biopharma (ZBIO) PT Raised to $52 at Jefferies |
| October 8, 2024 5:18 am | Roger Song | Jefferies | $35.00 | $18.70 | TheFly | Zenas BioPharma initiated with a Buy at Jefferies |
Latest News for ZBIO
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on April 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board…
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) shares rose 7.6% during trading on Thursday after an insider bought additional shares in the company. The stock traded as high as $22.12 and last traded at $21.9120. Approximately 666,115 shares traded hands during trading, a decline of 34% from the average daily volume of 1,006,415 shares.
Twist Bioscience (NASDAQ: TWST - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability. Analyst Ratings This is a summary of current
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate…
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that it has commenced underwritten public offerings of its convertible…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZBIO.
U.S. House Trading
No House trades found for ZBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.